Results 231 to 240 of about 52,753 (266)

Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people living with HIV in South Africa

Bodley N, Govender K, Moodley P, Samsunder N, Sookrajh Y, Turner PJ, Butler CC, Hayward GN, Gandhi M, Drain PK, Garrett N, Dorward J.   +11 more
europepmc   +1 more source

Brain structure of South African children born to mothers on dolutegravir versus efavirenz-based ART

Bradford LE, Wedderburn CJ, Malaba TR, Theunissen H, Ringshaw JE, Bourke NJ, Williams SC, He N, Read L, Waitt C, Reynolds H, Colbers A, Read J, Davel L, Orrell C, Taegtmeyer M, Wang D, Khoo S, Myer L, Donald KA.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efavirenz

Reactions Weekly, 2020
openaire   +2 more sources

A Concise Analytical Profile of Efavirenz: Analytical Methodologies

Critical reviews in analytical chemistry, 2021
Non-nucleoside reverse transcriptase inhibitors are the prime members of antiretroviral therapy that are presently employed for the management of the human immunodeficiency virus.
J. Ambhore, Suraj R. Chaudhari, R. Cheke, P. Kharkar   +3 more
semanticscholar   +1 more source

Efavirenz

Journal of the Association of Nurses in AIDS Care, 2000
Item does not contain ...
Aarnoutse, R.E., Burger, D.M., Koopmans †, P.P.   +2 more
openaire   +4 more sources

Efavirenz

Drugs, 1998
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which shows good inhibitory activity against HIV-1. Reduced susceptibility to efavirenz has been reported with HIV-1 variants containing single and multiple mutations to the reverse transcriptase enzyme.
J C, Adkins, S, Noble
openaire   +2 more sources

Efavirenz

Expert Opinion on Pharmacotherapy, 2007
Treatment of HIV infection is typically carried out using a combination of at least three drugs. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts by non-competitive inhibition of the viral enzyme. Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as ...
openaire   +3 more sources

Long acting Efavirenz and HIV-1 fusion inhibitor peptide co-loaded polymer-lipid hybrid nanoparticles (PLN): statistical optimization, cellular uptake and in vivo biodistribution.

Molecular Pharmaceutics, 2020
The objective of the present study was to develop long-acting Efavirenz-Enfuvirtide co-loaded polymer-lipid hybrid nanoparticles (PLN) with improved intracellular delivery to target T- and macrophage cells located in multiple HIV sanctuaries. Box-Behnken
Dhanashree H. Surve, Yugandhara Jirwankar, V. Dighe, Anil B. Jindal   +3 more
semanticscholar   +1 more source